“Investing in flow chemistry is an ongoing challenge in our industry, which has been using mainly one-batch production for over 50 years. These investments are the result of a change of mentality that is deeply rooted in our company, because we believe that this new paradigm can increasingly fill the existing technological gap in the production of active ingredients, offering ever broad CDMO services to pharmaceutical customers” comments Giovanni De Filippo, Fine Chemicals Sales & BD Head.
Flow chemistry allows not only to produce active ingredients in a continuous way, performing more accurate syntheses, in a more eco-sustainable and safe way, but also to manage hazard and challenging chemistries. These investments have allowed the company to make its platform "fully integrated", that is, able to support customer projects at any drug development stage, from process research & development up to industrialization.
In 2020, the company produced more than 300 tons of active ingredients, of which over 40% dedicated to custom development and contract manufacturing (CDMO).